The office in Uzbekistan will become the regional “hub” of Inpharmatis in Central Asia, noted the company`s CEO Dr. Polina Dombure.

“The pharmaceutical industry of Uzbekistan is developing dynamically, manufacturers are actively introducing innovative solutions both in the production and registration of medicines. Today, enterprises of the world's leading pharmaceutical manufacturers are represented in Uzbekistan, medicines are in demand not only in the domestic market but are also actively exported abroad. The representative office of Inpharmatis in Uzbekistan will become a regional “hub” for Central Asia. We are confident that more than 15 years of experience of Inpharmatis in the countries of the European Union and the CIS will allow our company to make a significant contribution to the development of pharmaceutical production in Uzbekistan,” said Polina Dombure.

Saidamir Sadikov, Head of the Inpharmatis representative office in Tashkent, said that: “The opening of an official representative office in Uzbekistan provides new opportunities for cooperation of Inpharmatis both with state regulatory bodies of the Republic of Uzbekistan and with pharmaceutical manufacturers”.

Inpharmatis considers the most promising areas for a partnership to be the automation of quality management in pharmaceutical production, electronic solutions for regulating access to the pharmaceutical market, GMP audits, and joint projects in the field of Regulatory Affairs and pharmacovigilance.

According to the Ministry of Foreign Trade of Uzbekistan, today there are 152 pharmaceutical enterprises in the country that produce 2,373 names of medicines. There are 8 research institutes and centers. In addition, the only plant in Central Asia is located in Uzbekistan, which specializes in the production of insulin used for the treatment of diabetes mellitus.